Document 0858
 DOCN  M95A0858
 TI    Fluconazole response patterns in HIV-infected patients with
       oropharyngeal candidiasis.
 DT    9510
 AU    Diz Dios PD; Alvarez Alvarez J; Fernandez Feijoo J; Castro Ferreiro M;
       Section for Special Patients, School of Dentistry, Santiago de;
       Compostela University, Spain.
 SO    Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Feb;79(2):170-4.
       Unique Identifier : AIDSLINE MED/95338932
 AB    A prospective study to assess the efficacy of fluconazole in
       oropharyngeal candidiasis in patients with HIV was conducted. A cohort
       of 30 HIV-positive persons with clinical and microbiologic confirmed
       oropharyngeal candidiasis (Candida albicans > 1000 CFU/ml) received
       fluconazole 100 mg daily for 7 days. In vitro antifungal susceptibility
       tests demonstrated a lack of fluconazole resistances. Cultures of mouth
       swabs were performed at the end of therapy and 2 weeks later. There was
       a clinical and microbiologic cure in 26 patients (87%). In 10 of these
       26, cultures remained negative after 2 weeks; most of them had CD4
       lymphocyte count > 400/ml. In the other 16 patients (53%), cultures
       showed a microbiologic relapse 2 weeks after treatment. In spite of
       clinical improvement, treatment failure was observed in four patients,
       all of them with CD4 lymphocyte count < 50 ml.
 DE    Candida albicans/DRUG EFFECTS/ISOLATION & PURIF  Candidiasis, Oral/*DRUG
       THERAPY/ETIOLOGY  Colony Count, Microbial  CD4 Lymphocyte Count
       Fluconazole/PHARMACOLOGY/*THERAPEUTIC USE  Human  HIV
       Infections/*COMPLICATIONS  Microbial Sensitivity Tests  Prospective
       Studies  Recurrence  Treatment Outcome  CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).